Q1 2025 Pfizer Inc Earnings Call
Good day, everyone and welcome to Pfizer's first quarter 'twenty 25 earnings conference call.
Today's call is being recorded.
At this time I would like to turn the call over to Francesca Demartino, Chief Investment Relations Officer, and senior Vice President.
Speaker Change: Go ahead ma'am.
Speaker Change: Good morning, and welcome to Pfizer's earnings call.
Speaker Change: Francesca Demartino, Chief Investor Relations officer on behalf of the Pfizer team. Thank you for joining us.
Speaker Change: This call is being made available via audio webcast at Pfizer Dot com.
Speaker Change: Earlier. This morning, we released our results for the first quarter of 'twenty twenty-five via a press release that is available on our website at Pfizer docs.
Speaker Change: I'm joined today by Dr. Albert boiler, our chairman and CEO and Dave Denton Rcs.
Speaker Change: Albert and Dave have some prepared remarks, and we will then open the call for questions members of our leadership team will also be available for the Q&A session.
Speaker Change: Before we get started I want to remind you that we will be making forward looking statements and discussing certain non-GAAP financial measures.
Speaker Change: I encourage you to read the disclaimers in our slide presentation. The press release, we issued this morning and the disclosures in our SEC filings, which are all available on the IR website on Pfizer Dot com.
Speaker Change: Forward looking statements on the call are subject to substantial risks and uncertainties speak only as of the calls original date and we undertake no obligation to update or revise any of the statements with that I will turn the call over to Albert. Thank you Francesca. Good morning, everyone. Thank you for joining our call. We are very pleased with our performance in the first quarter as we.
Speaker Change: To execute with focus and discipline on our strategic priorities.
We are strengthening our R&D organization in our efforts to advance our pipeline and productivity.
Speaker Change: Much demised into volume production in our commercial portfolio.
Speaker Change: And we are improving operating margins with our continued progress in making our company more efficient.
Speaker Change: In the current volatile external environment.
Speaker Change: Underlying strength of our business and strong relationships with government leaders across the world.
Speaker Change: All of us navigate with zoom.
Speaker Change: While we continue to engage in colon for contingencies, we are focusing day to day on what we can do to move our business flow.
Speaker Change: I want to emphasize our continued confidence that we are well positioned to enhance shareholder value.
Speaker Change: Okay.
Speaker Change: Now I will turn to our top strategic priority in 2025, improving R&D productivity as we advance our pipeline with sharpened focus.
Speaker Change: We are intensifying our rigorous commercial assessment and portfolio prioritization from early clinical development.
Speaker Change: This means we will be disciplined in monitoring our portfolio.
Speaker Change: Directing investment and attention to potential blockbuster or Mega blockbuster.
Speaker Change: And scrutinizing the total number of assets under development.
Daniel Teper: Oh, Daniel Teper, our announcement earlier this month demonstrates our commitment to this approach this.
Daniel Teper: <unk> continued the development of new people one of our candidates in obesity portfolio.
Daniel Teper: Although difficult was the right decision or the company.
Daniel Teper: Going forward, we are committed to building, our cardio metabolic pipeline, including obesity by advancing internal programs, such as our gift and Douglas and pursuing external opportunities that could include partnerships or acquisitions.
Daniel Teper: We will continue to be disciplined.
Daniel Teper: We moved the key decision points for our pipeline or our business development targets.
Daniel Teper: We believe we have the potential to address significant patient needs with differentiated approaches that focus on supporting optimal weight management and related conditions, we would work on potential medicines in combination regimens, but could be more accessible better.
Daniel Teper: Easier to dose and more effective in supporting the right effects on body composition and muscle mass.
Daniel Teper: In addition to sharpening our focus and internal medicine since expanding his role in January as our Chief Scientific officer.
Daniel Teper: Chris Bustle cause moves both thoughtfully and quickly.
Daniel Teper: It's shaping our R&D organization to also send their oncology vaccines and inflammation immunology and additions in combat.
Daniel Teper: Chris has enhanced his leadership team with some terrific additions we are recognized as leaders in their field.
Daniel Teper: But Richard Carver Jordan is our new Chief Medical Officer.
Daniel Teper: Jeff Legos, if you'd see oncology.
Daniel Teper: And Jimmy this is our new chief internal Medicine office.
Daniel Teper: These leaders each bring many years of experience deep expertise and proven track record in Guy I think the discovery development and approval of practice changing therapies and they are an excellent addition to our already strong cost hopefully theirs in R&D.
Daniel Teper: We are on track for a strong year of anticipated pipeline catalysts in 2025.
Daniel Teper: We are making progress towards anticipated multiple key milestones, including at least for regulatory decisions up to nine phase III Readouts and significant series of people adult program starts.
Daniel Teper: With one of our key oncology programs, we are aimed to bring forward. What these represent the first potential treatment advancement in more than 30 years four patients with BCG naive high risk non muscle invasive bladder cancer.
Daniel Teper: We are encouraged by a positive readout over the people with our phase III <unk> trial.
Daniel Teper: So suddenly in combination with BCG.
Daniel Teper: The current standard of care.
Daniel Teper: We presented the full data from this study this past weekend at the annual meeting of the American Urological Association.
Daniel Teper: Non muscle invasive bladder cancer is a condition predominantly treated by urologists.
Daniel Teper: In multiple market research and focus group studies.
Daniel Teper: Urologists stated a significant preference for a subcutaneous PD one because it can be used in their practices and eliminates the need to refer their patients to excuse me.
Daniel Teper: We also anticipate meaningful readouts this year for pets and pet owners.
Daniel Teper: That's it already is a core therapy in our oncology portfolio.
Daniel Teper: Pfizer plus temporary leasing them up is the most prescribed first line treatment for locally advanced Metastatic Bureau, celiac compensating the U S.
Daniel Teper: We are working to work more than doubling the total addressable patient population in the U S for pasta with potentially registrational in starting date, though we expect this year from ongoing studies in muscle invasive bladder cancer.
Daniel Teper: We are also watching tweets a significantly expanded population of patients.
Daniel Teper: With multiple me alone.
Daniel Teper: We are anticipating a phase two readout this year for Rex.
Daniel Teper: In a study for double class exposed to relapsed refractory multiple myeloma.
Daniel Teper: If successful and approved.
Daniel Teper: This would more than double the addressable population versus the currently approved indications.
Daniel Teper: In addition to the increased addressable population.
Daniel Teper: Moving to earlier lines of therapy is expected to increase the duration of treatment and potentially create an inflection point in <unk> growth.
Daniel Teper: We expect to begin pivotal studies for our investigational PDL one of adopting a b C.
Daniel Teper: Later this year.
Daniel Teper: This will be for first line metastatic head and neck squamous cell carcinoma, and second line non small cell lung cancer.
Daniel Teper: We also anticipate that far.
Speaker Change: First line people that study start for me.
Daniel Teper: E cigarettes.
Daniel Teper: This is a novel integrin better seeks targeting adopting a D C.
Daniel Teper: If successful and approved.
Daniel Teper: Opportunity to change the standard of care globally, So I do see expressing tumor.
Daniel Teper: Boldly say D C PDL onesie and SUV.
Daniel Teper: Potential first in class ADC is using Adobe paid.
Daniel Teper: But at least its immuno cell immunogenic cell death.
Daniel Teper: And in combination with an immune checkpoint inhibitor demonstrates significant results.
Daniel Teper: Early data for PDL, one Z and <unk> in combination with the temporary leasing them up pilot.
Carlos: Hi, Carlos.
Carlos: With both agencies, we are targeting non small cell lung cancer.
Speaker Change: The most frequently diagnosed constant globally.
Speaker Change: The leading cause of cancer related deaths.
Speaker Change: Lung cancer represents a substantial area of peso neat.
Speaker Change: A growing market with the highest projected CAGR in oncology.
Speaker Change: 27.
Speaker Change: In vaccines and another of our priorities set up Utica areas, we see opportunities to enhance and augment our strong position in the market.
Speaker Change: We are also planning a potential registrational study in adults later this year with our fourth generation basically be candid.
Speaker Change: With all four and six generation basically the candidates. We believe we can build on our leadership in the industry.
Speaker Change: Our fourth generation candidate covers twenty-five sewer pipes, including potentially improve immunogenicity for serotype three.
Speaker Change: Which is one of the largest remaining contribute this disease.
Speaker Change: We are also working to accelerate progress with our fifth generation candidate, which is in preclinical development and covers over seven serotypes.
Speaker Change: As we continue to scrutinize the number of programs you are actively advancing we will have opportunities to accelerate or add others to help address significant patient needs.
Speaker Change: One example is the recent accelerated start of a pivotal study for northern.
Speaker Change: Menstrual related migrate we'd.
Speaker Change: Suites is estimated to impact more than half, but women experience migrate.
Speaker Change: We look forward, providing future updates about our pipeline progress as we continue to sharpen our focus on our most meaningful programs in prioritized therapeutic assets.
Speaker Change: Well my cell experiments is all key categories seen another leap.
Speaker Change: In our kick out there was just another 2025 strategic priorities.
Speaker Change: More than a year ago, we decided to separate the U S and they've been ethanol operations.
Speaker Change: The leadership of our meter Malik Chief commercial officer, and Alexander <unk>, Our Chief International Michelle Officer.
Speaker Change: We refined our commercial model to bring heightened focus helping got strategic and prioritize our most impactful products and regions.
Speaker Change: It is working well.
Speaker Change: In the U S. Our team demonstrated its hawkish triangular hockey products and continuous improvement in execution.
Speaker Change: In international we are back to a personal growth in the first quarter across all parts of the division.
Speaker Change: This was the result of a prioritization and disciplined focus on key growth drivers to maximize our return and accelerate new product penetration back.
Speaker Change: Our performance was strong both in the U S and international markets across several key products, including the Pinnacle family Norfolk.
Brett: Hello, Brett.
Speaker Change: Our <unk> family.
<unk> family of products had robust growth in the quarter.
Speaker Change: Well, we are seeing the impact of competition with a new market and we anticipate this will continue through the year.
Speaker Change: We will work towards maintaining our market, leading ecosystem, but cars com from six years, establishing credibility and expertise with the cardiology community.
Speaker Change: Our team remains committed to addressing high unmet patient need by helping to improve diagnosis and ensuring appropriate patients with <unk> cardiomyopathy, you'll receive treatment.
Speaker Change: Demand continued to strengthen formulary.
Speaker Change: With the revenue growing 40% over their estimated in the court.
Speaker Change: Our commercial teams effectively engaged with health care professionals, and we were pleased with strong outperformance of our newly launched consumer campaigns.
Speaker Change: We are pleased with the continued strength also far oncology portfolio.
Speaker Change: That's it for example grew 25% of impressions driven by increased market share in first line metastatic Euro city outcomes.
Speaker Change: Hello, Brenda grew 79% operationally as we continued to see strong adoption with its emerging as a potential first line standard of care for patients with <unk> positive metastatic non small cell lung cancer.
Speaker Change: I am not is another key commercial category for Pfizer and we are drawing on our expense extensive experience in launching medicines in this therapeutic area.
Speaker Change: Familiarity among health care professionals continue to improve for single quits.
Speaker Change: Which grew 42 operationally in the quarter.
Speaker Change: Yeah.
Speaker Change: Our commercial team has continued to work.
Speaker Change: Towards increased patient access for this second keep it there for patients aged 12, pent up with moderate to severe atopic dermatitis.
Speaker Change: We submit full we are encouraged by the growth we have seen to date.
Speaker Change: We will seek to further unlock access to this advanced systemic treatment for patients with severe alopecia areata.
Speaker Change: These highlights so how we are positioned to further expand and sustain our performance trajectory among our key brands.
Speaker Change: And with that now I will turn it to Dave to speak about the other societies at priorities. Thank.
Dave Denton: Thank you Albert and good morning, I'll begin this morning by reinforcing the fact that our solid financial results demonstrate our strong execution focus we continue to concentrate on driving positive patient outcomes and delivering on our financial commitments, while navigating an ever complex external environment.
Dave Denton: Our productivity improvement programs continued to drive a more efficient organization enhanced by our strong operating margins in the quarter.
Dave Denton: Going forward, we expect to improve our cash flows reduce our debt leverage and have more flexibility for our three capital allocation pillars.
Dave Denton: Our focus remains on creating long term shareholder value, we will continue to invest in our business for the long term, while prudently returning capital to our shareholders.
Dave Denton: Now first let me start with our first quarter results second I'll touch on our capital allocation priorities and then I'll touch upon our cost improvement initiatives.
Dave Denton: Finish up with a few comments on the macro environment, and our 2025 guidance, which we are reaffirming today.
Dave Denton: For the first quarter of 'twenty 'twenty five we recorded revenues of $13 $7 billion, a decline of 6% operational.
Dave Denton: The decline was largely due to lower Pax lowered revenues in part due to last year's one time tax low bid revenue credit recorded in Q1 of 'twenty four.
Dave Denton: In addition, U S revenues were tempered by changes in the I R. A Medicare part D redesign, which took effect in the first quarter.
Dave Denton: Partially offsetting the decline was growth in several inline products in the U S and overall growth internationally.
Dave Denton: On the bottom line, we reported first quarter 2025 diluted EPS of <unk> 52 cents, a share and adjusted diluted earnings per share of <unk> 92 cents ahead of our expectations due to overall strong gross margin and cost management performance.
Dave Denton: Our performance continues to show that our refined commercial approach is working we continue to focus on key products and geographies the deployment of our commercial field resources globally, and the continued optimization of our marketing resources into key priority areas.
Dave Denton: We saw strong contributions across our product portfolio portfolio, primarily driven by the <unk> family commodity Pat's Abner tack in la <unk>, which were more than offset by declines in tax low bid Alec quest Xeljanz and high brands.
Dave Denton: Adjusted gross margin for the quarter expanded to approximately 81% primarily result of favorability include royalties, partially offset by unfavorable product mix.
Dave Denton: Focus on cost management across our manufacturing network will remain a priority.
Dave Denton: Total adjusted operating expenses were $5.2 billion for the first quarter 'twenty, 5% to 12% decline operationally operationally versus last year.
Dave Denton: Now looking at the components adjusted <unk> expenses decreased 12% operationally, primarily reflecting our ongoing productivity improvements driving a decrease in marketing and promotional spend spend for various products as well as lower spending in corporate enabling functions.
Dave Denton: Adjusted R&D expenses also decreased 12% operationally driven primarily by a decline in spending due to our pipeline optimization efforts expected to be reinvested later this year and into next year.
Dave Denton: We continue to be disciplined with our operational expense management.
Dave Denton: Q1 reported diluting diluted earnings per share were <unk> 52 cents and our adjusted diluted earnings per share were 92 cents, which benefited from our efficient operating structure and.
Dave Denton: In addition to favorable global income tax resolutions in multiple tax jurisdictions spanning multiple tax years as well as a favorable change in the jurisdictional mix of earnings.
Dave Denton: With that now let me quickly touch upon our capital allocation strategy, which is designed to enhance long term shareholder value our.
Dave Denton: Our strategy consist of maintaining and growing our dividend over time.
Dave Denton: Reinvesting in our business at the appropriate level of financial return.
Dave Denton: Making value enhancing share repurchases.
Dave Denton: In Q1, we returned $2 $4 billion to shareholders via our quarterly dividend.
Dave Denton: Invested $2 2 billion in our internal R&D and completed business development activity as expected was minimal.
Dave Denton: We achieved our 3.25 gross leverage target at the end of 'twenty 'twenty four a key priority towards improving our capacity for business development in.
Dave Denton: In addition, the monetization of our Haley on investment has contributed to our improved cash position.
Dave Denton: As a reminder, in January we monetized approximately $3 billion of R. Haley on shares and in March we monetize the last tranche of our <unk> shares receiving approximately 3.3 billion in net cash proceeds.
Dave Denton: With this sale, we have now fully exited our ownership inhaling.
Dave Denton: Overall, our objective remains to Delever, our balance sheet over time, which will further support our return to a more balanced allocation of capital between reinvestment and re and direct return to our shareholders.
Dave Denton: We continue to be disciplined on our operational expense management progressing multiple improvement programs as we remain focused on driving long term margin improvement over the coming years.
Dave Denton: We expect we continue to expect initial savings from phase one of our manufacturing optimization program in the latter part of this year with approximately one $5 billion in savings from phase one that's expected by the end of 2027 and.
Dave Denton: In addition, we are progressing the evaluation of other strategies to improve our network structure and product portfolio respectively.
Dave Denton: As part of our goal to return to our pre pandemic operating margins, we remain on track to deliver on our goal of at least $4 5 billion in cumulative net cost savings from our ongoing cost realignment program by the end of this year.
Dave Denton: And today, we've announced our expectation that this program will deliver an additional $1.2 billion in net savings primarily in <unk> and in part by leveraging digital tools, including automation and AI as well as simplification of our business processes. The savings are.
Dave Denton: I expect to be fully realized by the end of 2027.
Dave Denton: Furthermore, we have identified additional opportunities to drive improvements in productivity and operational efficiency in our R&D organization again through enhanced digital enablement as well as automation.
Dave Denton: We expect approximately $500 million in savings associated with these efforts to be realized.
Dave Denton: By the end of 2026 with the savings reinvested within our R&D program.
Dave Denton: Now in total we expect approximately seven $7 billion in savings by the end of 2027 to drive operational efficiency strengthening our business with the potential of contributing significantly to our bottom line over this period.
Dave Denton: Now, let me turn to our full year 2025 guidance.
Dave Denton: As you are aware the pharmaceutical industry is currently navigating a complex global landscape shaped by rapidly evolving trade and tariff policies to.
Dave Denton: To help navigate this fluid environment, we've established a cross functional team to analyze a range of potential outcomes, while developing strategies to help us mitigate the potential impact to our business in both the short as well as the long term.
Dave Denton: These actions include the management of current inventory levels in certain jurist jurisdictions, leveraging our domestic manufacturing footprint.
Dave Denton: And the potential production of certain API and products in the U S.
Dave Denton: Should we be impacted by further tariffs in the future we will assess the impact of these policies enacted and provide information at the appropriate time.
Dave Denton: Let me now spend just a few minutes our 'twenty 'twenty four 'twenty five guidance, which remains unchanged. It would be clear does not include the potential impact of future changes in trade and tariff policies.
Dave Denton: We expect total company.
Dave Denton: Full year 2025 revenues to be the range of $61 billion to $64 billion in full year 2025, adjusted diluted earnings per share to be in the range of $2 80 to $3 a share which reflects our expectation of strong contributions across our product portfolio.
Dave Denton: And our focused discipline on cost management as.
Dave Denton: As we finished Q1 with earnings strengths and excluding the potential impact related to future trade changes. We are currently trending towards the upper end of our adjusted diluted earnings per share.
Dave Denton: <unk> range.
Dave Denton: In closing, let me emphasize several key aspects of our business.
Dave Denton: We will continue our focus on executing to maximize the commercial value of our product portfolio and <unk> and we remain committed to driving value, creating innovation, while strengthening our pipeline.
Dave Denton: Additionally, our cost improvement programs are set to deliver operating margin expansion.
Dave Denton: Expected productivity gains will be driven by leveraging our digital capabilities and simplifying our business processes are.
Dave Denton: Our improved balance sheet step the stage for more balanced and enhanced capital deployment.
Dave Denton: <unk> focused on creating value for our shareholders.
Albert Boiler: That I will now turn it back over to Albert for Q&A. Thank you David operator, please assemble the Q&A, let's start the Q&A.
Speaker Change: At this time, if you would like to ask a question. Please press star one on your telephone keypad.
Albert Boiler: You may remove yourself from the queue at any time by pressing star two.
Speaker Change: Once again that is star one to ask a question.
Speaker Change: We will go first of all multi van with Guggenheim. Please go ahead.
Speaker Change: Great. Thanks, so much for taking the questions maybe two if I could so one just.
Speaker Change: I appreciate your prepared remarks, we can maintain the dividend.
Speaker Change: And your commitment.
Speaker Change: You are maintaining and growing the dividend over time, but I think we've just gone through increasing.
Speaker Change: <unk>.
Speaker Change: Industrial over the last few months.
Speaker Change: Especially with some of the tariff uncertainty and how that might impact cash flows.
Speaker Change: I'm talking about maybe getting more active on the business development side, So maybe just to reinforce that.
Speaker Change: One more time and nothing else just taken their level of commitment out there. Even if there is an impact from the tariffs side, you still feel comfortable in being able to maintain and grow that.
Speaker Change: And then my second question David.
Speaker Change: Okay.
Speaker Change: Go ahead, sorry, Okay, Yes, I just had one other if I could just on the Covid business and just give US you have to understand the nuances around the technical details this quarter.
Speaker Change: Clean fuels become Liam here, but do you still see that business being relatively stable. This year relative to last year or has that changed from what your expectations are at the beginning of the year. Thank you.
Speaker Change: David will tell you about dividend and then Amir.
Speaker Change: Xander about the Gulf Yeah, Vermeil, clearly consistent with my prepared remarks, the dividend remains a critical component and a key component of our capital allocation strategy. As you can tell we've been very focused on improving the operating margin performance of our business, thus improving our cash flow yield over time. This is all in support of all of our capital allocation.
Speaker Change: <unk> priorities with dividend being a key component of that.
Dave Denton: Thank you, Dave and let's start with EMEA.
Speaker Change: Thanks, Neil So you asked about <unk>.
Speaker Change: Thanks, LUV at utilization trends very closely to infection rates and we see a 50% treatment rate in close to 80% per common rates when there's infection. When we set up a very good commercial model to do that I think what you saw in Q1 was largely the function of the fact that we have a lower winter weight, but we still treated.
Speaker Change: 750000 patients starting the year with about 100000, a week and tapering off at around 35 to 40000.
Speaker Change: And while these numbers are lower than the consensus numbers it very much in line with our expectations and what we track or the business and what we've seen in multiple years now is that over the course of the year you have two COVID-19 waves one in the summer and one in the winter the peaks and valleys in the timing of those vary but we.
Speaker Change: Have had consistently multiple waves in our baseline assumption is that we will have those waves. This year as well and that we will be able to execute our business, including our tax utilization in the way that I described consistent with those waves.
Speaker Change: We've also set up a model, where we can successfully transition the Medicare Pap patients out of a U S G and into our traditional Medicare model a.
Speaker Change: Beginning March 1st of this year and so we can't predict exactly what the timing and shape of those waves will be but we're ready to execute again.
Speaker Change: Yes International Ah I will start with <unk> as you know international come out he is bigger than tax levied on command actually we beat consensus quite nicely with it by 130 million essentially driven by execution as you know our international December is in the Q1 of 2025. So in December we continue to execute.
Speaker Change: All contract you can in Europe and in companies you have setup like here in Japan, we maintain very strong leadership there until the end of the vaccination now as we move into Q2 and Q3, we will start actually shipping all vaccine in 2000, and <unk> countries, where vaccination campaign. He is going to stop and in particular in Brazil the way we.
Speaker Change: One is the two year contract for adults, which is a very Bolton vaccination country now.
Speaker Change: When we talk about <unk> actually the smaller internationally and we performed as we expected we have now a packs they need a commercially sold in 49 markets. So there is no more advanced but chasing kind of minimum so it's really a associated with utilization the point is.
Speaker Change: In international where we have actually low utilization compared to the U S. We still need to do some work in terms of utilization and treatments. Thank you Alexander operator. Please next question.
Speaker Change: We'll go next to Evan <unk> with BMO capital markets.
Evan: Hi, guys. Thank you so much for taking my question and I didn't want to touch on the reasons for the Daniel discontinuation.
Evan: Wanted to look forward as you think about a potential obesity asset what are some key aspects of the profile you're looking for either from an internal perspective or potentially externally. Thank you so much.
Speaker Change: Let's start with Chris and then they go to Andrew Thanks.
Speaker Change: Thanks, very much thanks for the question, yet and as Albert has stated that it probably was the right decision for Pfizer based on totality of data.
Speaker Change: And as we stated previously a single ICM to let's not take participant in the dose optimization study with about the dose titration experienced a potential drug induced liver injury, which recovered rapidly after treatment discontinuation or do we not 100% sure. This is due to delek <unk> broadened the risk was high enough for us to do.
Speaker Change: Discontinued the program, while still being committed to obesity and employing our global resources what are the opportunities cardiovascular metabolic. It's one of our core strategies within internal medicine, an area with significant remaining unmet need and just as a reminder, obesity alone up to 60% of patients.
Speaker Change: <unk> continued current approved medicines. After 24 months, we will continue to apply our global capabilities to advance our pipeline of differentiated our own medicines, including our oral <unk> antagonist currently in phase two and then condensate our preclinical portfolio to the clinic.
Speaker Change: We believe the future will be more fragmented based on differentiated or unique combinations with an emphasis on tolerability accessibility and convenience the future, but also become more personalized space on combinations addressing specific diseases.
Speaker Change: Associated with obesity, and metabolic dysfunction, including neurology, cardiovascular and respiratory and Andrew.
Speaker Change: Yes, I mean, Chris gave you a faithful answer.
Speaker Change: Just underline that although you referenced the BCG that role I think curtains and potentially other.
Speaker Change: Modalities targets more broadly needs not to be underestimated and obviously this extends beyond cardiovascular medicine than we're interested in all the potential opportunities that exists for these molecules in terms of which assets or which portfolio of assets, we're seeking to build.
Speaker Change: I think there's two axis number one obviously is clinical differentiation and output referenced some of the ways. You can do that in terms of scheduling tolerability muscle preservation, but they're at this too, but then separately, there's commercial differentiation, which really references the indications that we pursue so I hope that gives you some idea of the <unk>.
Speaker Change: Travel and when we have something to say you will not be the first tonight.
Speaker Change: Good to know thank you next question please.
Tim Anderson: We'll go next to Tim Anderson with Bank of America.
Speaker Change: Yeah.
Speaker Change: Hi, Thank you I have a question on tariffs I figured if anyone's close to visit probably Pfizer Albert King as your chairman of pharma.
Speaker Change: If sector specific tariffs come through do you think that's likely to be think that 232 investigation route.
Speaker Change: Do you think you can still happen somehow through the.
Speaker Change: E P. A route to me it seems like it would be $2 32, but not everyone agrees.
Speaker Change: And in your past by some timing for when that one might have more information from the administration and then the last question is it absolute pipe dream to think that sector specific tariffs might really only be applied.
Speaker Change: Hi.
Speaker Change: Countries that current impact.
Speaker Change: A threat to national security like China.
Speaker Change: It's hard to see Ireland, paying and EMEA at the country.
Speaker Change: If I can get them and I would agree.
Speaker Change: It was the last the comment that you made also but let me tell you where we stand with who starts first of all we.
Speaker Change: We had on April 2nd and executive order about basically place targets.
Across the board everything, we can see or feel or dream, except with things pharmaceuticals and the semiconductor.
Speaker Change: Clearly there is risk going forward, but it's a very very different ballgame. If you are part of the tourist and you hope to be excluded then you are not part of it and try not to be included.
Speaker Change: Then on April 14th of April.
Speaker Change: There isn't made even more clear what is their concern with the pharmaceutical sector at all.
Mr Gates: Mr Gates.
Speaker Change: And they made it clear by launching it through at 232, which as you pointed out. If these investigations are is a connected with national security threats. This is not something new.
Speaker Change: First thrombotic munis today, some had expressed a serious concerns about the several essential medicines that they are made are outside the U S. The buy them continued with its concerns.
Speaker Change: The Trump administration has also released but it created with those medicines in the first one and now with the second Thrombectomy, Australia. So not only it's a little bit to 32 Bucks through my discussions with the highest levels of the government.
Speaker Change: They are concerned about this as their primary.
Speaker Change: The consumer and I think it is legitimate I think no country wants to have a critical medicines produce outside of the country, particularly they don't want to have critical mass. This is produced in the countries that are but.
Speaker Change: Tensions are high or can be a salad.
Speaker Change: And so.
Speaker Change: There is I think a very clear distinction in the way that they look at it in terms of what products. They are talking about and that is a very clear distinction as to what comes from friendly countries or what jobs from August 30 countries.
Speaker Change: So with all of that in mind and knowing that we are engaging in to have very productive discussions with all of the secretaries that are involved and at white house stopped without involved into votes I'm cautiously optimistic as I said, given the data that we have not been there and and I hope that we will know whether it is successful.
Speaker Change: We work with each of them instead of simply make sure what their concern of National Securities.
Speaker Change: It will be addressed with the best possible way.
Speaker Change: I think buck.
Speaker Change: The only question right, yes, so let's go to the next.
Speaker Change: A question please.
Speaker Change: We'll go next to Steve Scala with PD Cowen.
Steve Scala: Thank you and two questions. The first one is very similar to the one that Tim just asked and that is Albert given your unique insights into the thinking in Washington, do you think MF and legislation is only the most remote of possibilities or even simply not going to happen.
Steve Scala: And then secondly, what is the percent utilization of the U S plant.
Speaker Change: It is it's great to have this vast network in the U S. But if there is little or no.
Speaker Change: Excess capacity and your flexibility then it's a more limited advantage. Thank you.
Speaker Change: Oh. Thank you. Thank you very much for both questions.
Speaker Change: Look on the M. S. N first of all I can't speak about what would be the intention of the government, but I can comment on what actually is so hot and.
Speaker Change: The President issued an executive order that was focusing on pharmaceuticals.
Speaker Change: Very very expensive so cover a lot of topics over that.
Speaker Change: M. S. N was not mentioned, although they're under contract well. It wasn't mentioned in November there was the appeal panels, but he instructed so that we will find ways to resolve what was mentioned over there was BB M resort.
Speaker Change: And processing rebates, so the face.
Speaker Change: What was mentioned in November there was 340 bps 44, so I would say about the.
Speaker Change: Clearly one can say that when the president Eastern sent executive Order then you can read into what are the priorities of the administration and I think that so far what the way I have seen it at this.
Speaker Change:
Speaker Change: Uh huh.
Speaker Change: The old penalty. It is reported to be it is the <unk> reform and it is to lower.
Speaker Change: The cost for the patients because right now in the U S. The patients they are paying disproportionately out of pocket for their medicines compared to other medical intervention. So that's my.
Speaker Change: To send some box and again I'm cautiously optimistic, but nothing is certain and we are working continuously to influence.
Speaker Change: The the thinking and the decision making in particular understanding what is it that they want to let's say so that we can provide.
Speaker Change: Productive solutions on the percentage of utilization of all our manufacturing sites first of all it is quite good.
Speaker Change: Good that we don't want to go through the details, but there is ample room. If there is a need to transfer production to accommodate a we've had huge manufacturing capacity right now.
Speaker Change: The U S, particularly for everything but this is injectable.
Speaker Change: And the our ability if there is a need.
Speaker Change: Is clearly there.
Speaker Change: With all of the meat to build new facilities, just utilize the current wants and to transfer production of that with that let's go to the next question.
Speaker Change: We'll go next to <unk> with Evercore ISI.
Speaker Change: Hi, guys. Thanks for taking my question I have two here if I may 1st is on dividend and second as a follow up to something Albert mentioned.
Speaker Change: First on dividend I know, there's obviously eloise coming up over the next three three to four years with net income and free cash flow pressures, how much of that pressure could be offset by potential opex cuts that you're taking underway. I guess said differently can you hold net income at or near the current levels. That's.
Speaker Change: Part one of the question and then also.
Speaker Change: If a tariff impact approaching I don't know, 15% to 20% of Bottomline kicks in and can you still confirm your debt.
Speaker Change: It meant to dividend and finally, Albert you mentioned the distinction between friendly versus unfriendly countries, but in the initial tariff announcement that didn't necessarily seem to hold true. So while should that apply in the case of pharma. Thank you very much.
Speaker Change: Thank you Dave why don't you take the dividend yeah, So uber or clearly in my prepared remarks, and what we said very consistently is our objective is to improve our operating margin performance over time, and we've said that knowing quite well that we have eloise approaching.
Speaker Change: Some of the improvements in productivity that we are making are in design to improve it.
Speaker Change: To improve operating margin in the face of those eloise at the same time, our business is actually evolving such that particularly in the oncology space, where we're leaning into that business and those products actually yielded very high gross margin and operating margin performance. So the short answer is yes, we can.
Speaker Change: We can withstand that and secondly, we're very focused on improving our operating margin over time in the face of those eloise.
Speaker Change: Clearly our you've also heard us reiterate very specifically our focus is on maintaining and growing our dividend over time, and we would continue to do that.
Speaker Change: And we work hard to understand the environment looking forward and I don't want to hypothesize on what could happen, but it clearly we're watching the situation closely and our commitment to dividend is steadfast.
And I think David you made those are very clear quantity Duffy.
Speaker Change: Our calculations of what we expect when we put the number out there we know that we can keep it then David spoke about $7 billion by 2027, while maintain.
Speaker Change: The R&D at the current levels of investment, which I think it is a key strategy to offset festival navigate an uncertain environment. That's the best way to do it used to be product. Another comment I want to make one but because of that the cuts are not across the board or theyre not by just reducing resources there.
Speaker Change: There are very strong and they are happening first of all with the deployment of technology AI retinal says dramatic impact that waste that we have able to secure.
Speaker Change: Cost reductions and digital technology in general, but also through significant business simplification, but you are implementing and we looked at every single thing of how we do things and you know when you find a simpler thing so doing it.
Speaker Change: A significant cost element associated so all in all I think it's.
Speaker Change: As Dave said, we have our targets since we are very confident you can calculate that the we made them public and we're very confident but we will see them, but they get up in the 27.
Speaker Change: Regarding the partnership that would be on on friendly or unfriendly Congress Ooh I, it's up to the government to decide what they want to do but the is very very clear in my discussions, but the national security concerns is what I can get my discussions with National security concerns are.
Speaker Change: Pretty much associated not with friendly countries.
Speaker Change: Okay. Thank you next question please.
Speaker Change: Yeah.
Operator: We'll go next to Chris Schott with J P. Morgan.
Chris Schott: Alright, great. Thanks, so much just maybe first question on guidance.
Chris Schott: Pfizer's gross margins for this year or we should we still think about full year gross margins in the mid Seventy's range or has that changed at all following some of the upside with <unk>.
Chris Schott: And maybe just had a second part of that I'm just interested in a level of conservatism that's baked into the guidance here. It seems like the year is off to a very strong start, particularly on the cost side and just as we think about the progression. The rest of the year should we think about any offsets from the upside we saw this quarter. Thank you.
Speaker Change: Yeah. Thanks, Chris Dave here clearly, we are very confident in our outlook for 'twenty 'twenty five AC as you noted we ended we finished Q1 in a position of strength both from a top line and a bottom line perspective as I look at our operating plan, we've exceeded both topline and bottom.
Chris Schott: Line in Q1 based on our expectations internally, so we're off to a very solid start.
Chris Schott: Lee as I look forward. We're in Q1, we have a three quarters left to go I look at us maintaining our guidance range, but giving you. Some color that are top of it we're essentially derisking the balance of the year from a financial delivery perspective.
Chris Schott: We're still faced with some uncertainty from a macro environment perspective, so we're watching that cautiously at the same time, we're prepared to go into the vaccination season in a position of strength, but really was still some uncertainty around.
Chris Schott: How the macro environment might play out in that space as well. So I hope that helps I think from a gross margin perspective.
Chris Schott: To a nice start we haven't changed our guidance in our color on that but we're continuing to focus on improving our gross margin over time and improving our operating margin over time, which I think is even a more critical component for us and if you look.
Chris Schott: In Q1, we posted a little over 40% from an operating margin perspective was really solid performance. So again off to a really solid start.
Chris Schott: Thank you. So you don't have any concern about this in your guidance.
Chris Schott: Hi, Bill.
Speaker Change: She is the best let's move to our next question.
We'll go next to Geoff Meacham with Citi.
Geoff Meacham: Hey, guys. Good morning. Thanks for the question two quick ones, Alberta, Andrew just from a strategy perspective, what would you say ranks as a higher priority.
Speaker Change: With respect to how you tier.
Speaker Change: Would be multiple BD options is it the Tam is it sales through low is at peak sales after wasn't sure how much that's evolved.
Speaker Change: The current macro backdrop and then.
Speaker Change: I guess a question for Albert what incentives would you want to see and tariff negotiations that would maybe tipped the balance for Pfizer to increase manufacturing investments here in the U S.
Speaker Change: Yes.
Speaker Change: Yes on the slide that that maybe I can make some comments and then I ask also Andrew.
Speaker Change: It is very clear that we are facing and everybody knows alloys.
Speaker Change: Those alloys are starting in 'twenty six 'twenty 728, 26 smaller number I'm glad to say that it's a bigger number 28 is the biggest number.
Speaker Change: Then goes down.
At least at one time, you bet right. So to prepare for that we've had significant number of new launches, but they are growing.
Speaker Change: And we did significant business development, but it is growing because they were all early assets. What we bought so there were let's say having in front of them the growth period. So what do you project. It is not the most growing assets will offset the alloys in 'twenty 600 to 778 more or less so.
Speaker Change: And then following that because of course alloys are one time event. They continue growing and then we have a significant step up in the growth when they lost their Lloyd is going up.
Speaker Change: Now what is our strategy in addition to having business development and your product launches as we know that with the alloys. We are not going to be a strong top line growth story for the next three years given the alloys, we expect to become a EPS growth story and this is why you see here right now.
Speaker Change: The very acute focus on AR or improvement of margins also we expect even more importantly, what it would be a pipeline story during the next three years.
Speaker Change: We are very focused in the R&D productivity.
Speaker Change: We are learning from mistakes in the R&D productivity.
Speaker Change: Are moving with a very decisive steps to bring in your phase three studies and I think once they start they start also people will start modeling in their models.
Speaker Change: Or upgrading.
Speaker Change: Very probabilities of success as we are moving to say, but he started this to reflect what I. Just told you about the as the pipeline matures. The growth post 28 should look are among the top tier of the industry. So that's more of a lizard strategy.
Speaker Change: But within that we have $10 billion to $15 billion of capital to allocate but we are very prudent in how to do it and Andrew will speak about it.
Speaker Change: But.
Speaker Change: Bottom line. It is that we would have.
Speaker Change: <unk> seen the first three years and multiple expansion given the maturation of our pipeline.
Speaker Change: And of course.
Speaker Change: And EPS growth given our.
Speaker Change: Strong focus on the costs and Andrew and the bidding will be bumps all of them what do you think.
Speaker Change: So just on the I think Albert gave you have a very clear answer.
Speaker Change: Outset, just picking up on the specific question you asked I think it's all the above.
Speaker Change: Hello.
Speaker Change: As well as obviously as values I think the other thing I would also add that perhaps you didn't mention is that we built sustainable franchises and I'm thinking more of a longer term in the shorter term, but we need to have Greg and Joe rapidity, just as we've done internally with expanding and building on our <unk> franchise with a novel CDK four C Q2s.
Speaker Change: We have other assets as well within breast cancer SME, such as BT as another tool with an optional to built on the internal discovery and development that we have with our existing pipeline.
Speaker Change: Yes on the Tigris negotiations that you said that.
Speaker Change: What would you expect to see so that you'll be investing in the U S. I think is certainly.
Speaker Change: If I know about that will not be tourism to heavy certainty than there are tremendous investments that can happen in this country, both in R&D and manufacturing.
Speaker Change: And there is one is the tax environment.
Speaker Change: And a lot of manufacturing outside the U S has significantly changed.
Speaker Change: We have a global.
Speaker Change: Minimum tax.
Speaker Change: Around 16%, but has been established alright and also.
Speaker Change: Good thing the U S. Although.
Speaker Change: When President Trump did the first box, we had a huge inflection of capital coming back from Pfizer and others.
Speaker Change: And now I'm sure and I know, because I've talked to him, but he or she would like to see even a reduction in the current tax regime, particularly for locally produced goods. So that would be a huge incentive to also bring manufacturing here right and.
Speaker Change: But that requires a lot of capital and when in periods of uncertainty everybody is controlling their costs as we are doing in Venice.
Speaker Change: Very frugal with their investments as we are doing so that we have prepared for a rainy day. So that's what they want to see.
Speaker Change: Thank you very much next question please.
Trung Nguyen: We'll go next to Trung Nguyen with UBS.
Trung Nguyen: Hi, guys. Thanks for the question.
Trung Nguyen: Just another one on costs and guidance and one on BD. So on your cost realignment program, you announced an additional $1 2 billion savings by 27, how much of that can come out in 'twenty five and how should we think about the step up of costs for the rest of the year. Following what seems to be you guys exceeding.
Trung Nguyen: Our savings targets.
Trung Nguyen: Reiterating our guide.
Trung Nguyen: And then on BD you have mentioned.
Speaker Change: External opportunities how much is that macro environment impacting your decision in the timing of BD, given the volatility and unknowns and then on the other side of the table do you think centers are hesitating, given valuations are meaningfully lower than the start of the year. Thanks.
Speaker Change: Okay, David why don't you take the guidance and then Andrew you can because there'll be deal with them, but I will also comment on the <unk>.
Speaker Change: Cost side keep in mind that we're focused on taking four 5 billion out by the end of this year well on track with that the additional $1 2 billion that we've identified.
Speaker Change: Probably modest delivery of that in 2025, most of that in 'twenty, six 'twenty, seven, but maybe a little bit.
Speaker Change: From a R&D perspective, the $500 million that we're saving in improving productivity in R&D largely that will happen. This year to be reinvested in R&D late this year or maybe even bleed into next year to some degree.
Speaker Change: Thank you and on BD, Andrew valuations are low I'm starting to go is fine. So how would you see if things, yes, I mean, I think as you might imagine with with very awakes external environment, but with comfort.
Speaker Change: A $10 to 15 billion budget that they've had to be forecast at the or gave.
Speaker Change: Getting to this yet in <unk>.
Speaker Change: So the question of <unk>.
Speaker Change: Sellers adjusted to that new valuation the market supply and I think it depends I think generally it takes some time and some categories, where there is increasing therapeutic density because there's an ever expanding array of assets, mainly coming from China. I think that's an additional four switches, causing companies to become more Mena.
Speaker Change: To lower valuations, but I think it really depends.
Speaker Change: I'm trying what I tell my team constantly like this never let a good crisis go through ways and with prices. There are risks, but also there are tremendous opportunities because things obtains restock destroyed chains, so you'll need to be strategic and it would be smart you need to be disciplined, but you will need.
Speaker Change: Yes.
Speaker Change: Warren Buffett said.
Speaker Change: Cell.
Speaker Change: When prices are high and buy when prices are low.
Speaker Change: This alone.
Speaker Change: Next question please.
Speaker Change: We'll go next to Kerry Holford with Aaron Berg.
Speaker Change: Thank you and a question for me personally in the context of the U S.
Speaker Change: Yes.
Speaker Change: Okay.
Speaker Change: Mike Hello, Hello propulsion.
Speaker Change: U S truck sales okay.
Speaker Change: And in the U S.
Brian: Can you go ahead go ahead Brian.
Speaker Change: Okay.
Speaker Change: And then a question for Dave.
Speaker Change: Cogs can you just quantify the U S.
Speaker Change: Of that we anticipated that estimation.
Speaker Change: In Q1.
Speaker Change: Can you tell us what that specifically relates Ken just to confirm that.
Speaker Change: In fact, it could be a one off.
Speaker Change: Thank you.
Speaker Change: Well, thank you guys.
Speaker Change: Which percentage of production, we have here et cetera, but we are not disclosing this information. So we won't go into both of these.
Speaker Change: When it comes to the impact of the U S. Dollar I will ask Dave to comment. They made they've also you speak about the impact of higher rate.
Speaker Change: People can get a good picture of the puts and takes of the first quarter sales yeah sure. So maybe let's let's take this in.
Speaker Change: In points here first I know theres been a lot of volatile volatility in FX and currency fluctuations. If you were probably an outlier in the sense that we gave guidance in December. So if you look point to point from December to now FX is largely in.
Speaker Change: Immaterial to us given the fact, there's been a lot theres been a roller coaster ride to get from point a to point B, but right now FX is largely <unk>.
Speaker Change: And impact to Q1 and for the balance of the year. Secondly, if you look at <unk>.
Speaker Change: Medicare part D redesign in Q1 is dampened our U S revenues by approximately $650 million as we expected that dampening will lessen in the back half of the year as we continue to offset that a bit with.
Speaker Change: Incremental prescriptions.
Speaker Change: Third included in our guidance that we Didnt really speak about is there are some tariffs in place today.
Speaker Change: We anticipate those tariffs to be approximately $150 million for 2025, we are contemplating that within our guidance range and we continue to.
Speaker Change: Then trend to the top end of our guidance range, even with those costs to be incurred this year. Thank you. The next question. Please.
Speaker Change: We'll go next to a cash tomorrow with Jefferies.
Speaker Change: Okay. Thanks, so much.
Speaker Change: I realize there's a lot of uncertainty on tariffs, but hearing Mark gave color on Q1. It seems like some of your peers are hinting at the bottom line impact of tariffs could be manageable. So let's say the tariffs are broadly 25% on your transfer price, which I'm sure is a scenario your teams plan for.
Speaker Change: Would it be fair to say that the bottom line earnings impact would be a single digit percent basis with reasonable mitigation steps. Thank you.
Speaker Change: Thank you all guys I will never go through about the statement and we have made statements in the past.
Speaker Change: We have been burned so I'm very cautious.
Speaker Change: And careful about that before that our thoughts we have detailed contingency plans, but there are minimizing they embark but I'm.
Speaker Change: Right now focusing more on the fact that we should not have daughters and only if we kept.
Speaker Change: We should.
Speaker Change: Tried to implement measures I'm sure all companies are doing the same.
Speaker Change: Sorry, I can't be more specific I know youre in but it's not about let's go to the next question.
Speaker Change: Question. Please.
Speaker Change: Yes.
Speaker Change: We'll go next to Terence Flynn with Morgan Stanley.
Speaker Change: Yeah.
Speaker Change: Great. Thanks for taking the question maybe two for me.
Speaker Change: Another one on tariffs I know Scott Gottlieb, who is on your board referenced a grand bargain on the news a couple of weeks ago, and you've given a lot of color here, Alberta in terms of your discussions with the administration. So you can can you confirm if something along those lines is in the works.
Speaker Change: And the second question is on the pipeline that you guys and your partner venous recently reported some phase III data for <unk> from a <unk> II study just wondering how that data change or impact your strategy for this drug in the frontline setting. Thank you.
Speaker Change: Thank you very much I'm wondering I'm not aware of so Scott.
Speaker Change: While most of the Grand bargain a step closer follow chemotherapy, but also more importantly, I speak with him very well, but irregularly very very often see advisement several topics, but I don't know.
Speaker Change: Comments on Grand bargain and clearly right now.
Speaker Change: Two things on the horizon, one it is an executive.
Speaker Change: Wanted piece at 232 process on the Taurus or pharmaceuticals or that have been excluded from our overall totters geographic others broke out daughters and lots of National security, but there is also an executive officer of the president.
Speaker Change: So focusing on the 34th debate.
Uh huh.
Speaker Change: Reducing the cost of basins PBS reform, removing the pill panels and those are the things about the we are engaged right now not in any other type of buckets and then on that arena. So I will ask Chris to comment on that.
Chris: And thank you for the question as you know the phase III top line results.
Speaker Change: That would take two was and reported in March to the end.
Speaker Change: The last two months and we met the primary endpoint in the estrogen receptor one mutant population, which was statistically significant and clinically meaningful for progression free survival and overall survival still too early very immature and but.
Speaker Change: But we did not reach statistical significance and improvement in PFS in the intent to treat overall population and we plan to present detailed results at <unk>. It's a late late.
Speaker Change: Late breaking oral presentation, and we'll also start sharing the data with global regulatory authorities to potentially support regulatory filings. We are continuing the combinations with CDK for a 10 was tightlipped, which we're excited about as well as with cat six from this product on this project with that tech spend the combinations with <unk>.
Speaker Change: <unk> and shell they work with and Venus.
Speaker Change: Yes.
Speaker Change: To not just only filed that work without being as to discuss future plans for the phase III program.
Speaker Change: Okay. Thank you Chris.
Speaker Change: Next question please.
Speaker Change: We'll go next to David Risinger with Leerink.
David Risinger: Thanks, very much and thank you for all the updates.
David Risinger: I have two questions Albert first current Washington leadership is very supportive of the traditional technology sector, but it's taking the opposite approach towards biotechnology. So notwithstanding a few of the things that you mentioned that might be marginally positive such as.
David Risinger: The pill penalty.
David Risinger: Washington is actively degrading proven medical science collapsing, the NIH and driving reduced investments in the biotechnology sector in the United States could you please comment on that and how.
David Risinger: How you and other Biopharma companies are responding when you engage with Washington, and then separately.
David Risinger: With respect to the $2 32 investigation.
David Risinger: Since we can't see what's going on outside could you just explain exactly how that investigation is progressing.
David Risinger: How Pfizer is engaging on the $2 32 investigation front and what we should watch and when when when we when should we see news on $2 32. Thank you.
David Risinger: Yes. Thank you.
David Risinger: Clearly concerned about several of the statements that we have seen and approaches are.
David Risinger: Got it and USDA and some statements that they are not.
David Risinger: In correlation with what science.
David Risinger: <unk> has proven over the decades, and let them Boston majority of the scientific community when.
David Risinger: When I say Vos and 13 99, 9%.
David Risinger: And sometimes they are used this four 1%.
David Risinger: 0.2 challenge remains so I think there is scientific truth and that scientific truth. It is well presented and this is not only a U S thing is not only the CDC and the FDA and NIH, but it is the U K.
David Risinger: So far it is and it is the French special authorities the Spanish authorities.
Speaker Change: Corey until cohorts in.
Speaker Change: Israeli and I can go on and on so this think.
Speaker Change: Think of a conspiracy theory, but you know if someone is not that the whole world and they all fly.
Speaker Change: This over the wall.
Speaker Change: Once we implement our own sites. So I am very convinced that we are in the right side of history.
Speaker Change: Those people are in their own but I want to tell you that.
Speaker Change: The.
Speaker Change: Those of us or not.
Speaker Change: The expressed by the entire administration and there are many people, but they don't share those years and I.
Speaker Change: I would say that we.
Speaker Change: We had also a precedent, but he spearheaded the worst speed operation then she created this a miracle.
Speaker Change: Let's say I mean.
Speaker Change: There was no other country, but had done something like letting the world in the entire world was able to save the economy since survives based on what the production of course, we did the president and members of.
Speaker Change: Copies of their time on SAP.
Speaker Change: And.
Speaker Change: All of them, but they work with us to do it actually I'm talking about excuse me.
Speaker Change: The Nobel Prize for that was.
Speaker Change: Unfair, but if you did.
Speaker Change: It was severe Sirius from spirit.
Speaker Change: Its contribution.
Speaker Change: But.
Speaker Change: The thing that I discuss with everyone in the administration and I think that resonates settle up with Democrats and Republicans with everybody in the administration, including.
Speaker Change: It says every where he thinks that signed.
Speaker Change: <unk> right now.
Speaker Change: Progressing with the speed of light.
Speaker Change: Theyre signings.
Speaker Change: Biotech if these dominant.
Speaker Change: The U S is the dominant scientific positioning by effects, because we have created recycle sistema biotech and pharma and academia.
Speaker Change: Academia and all of that this exactly what segments have replicated in the last four years and in the last quarter, Yes, you're right. It was a significant setback for us, but took down a lot of funding for the price.
Speaker Change: Private the private sector, what's biotech the biotech small currently also because of tariffs, but also because of the four previous years. They are at historical low.
Speaker Change: And.
Speaker Change: As a result, there is very little money going through their biotech, but saying it's doing the opposite.
Speaker Change: And right now they are having very very good science and I think that's something about the vase.
Speaker Change: They sued everybody become share and they should be concerned not only for commercial parcel for national security point of view imagine if in the next.
Speaker Change: But dammit.
Speaker Change: The medicines that will help.
Speaker Change: <unk> been venting in this country, but none of that.
Speaker Change: That would be a problem.
Speaker Change: The 232 Investor day, so if there's any of us to get some but it was basically is launching and then the secretary of Commerce is running it is oh.
Speaker Change: Gathering information to see if there is any national security risks.
Speaker Change: That way, but the medicines are available in the U S supply chain of limits.
Speaker Change: The processes loans, they have requested information publicly and.
Speaker Change: Companies were so busy formation the farm Association, where suddenly the information everybody who has I mean, there are some that will submit information and probably proposals and those things will be assembled all of all.
Speaker Change: The time is this.
Speaker Change: Process is time limited, which I think is 270 days I don't recall well, but it is a I think.
Speaker Change: They need to complete to.
Speaker Change: 70 days.
Speaker Change: Knowing how fast this administration works I think that will do their work faster.
Speaker Change: So let's go to the next question.
Speaker Change: Okay.
Speaker Change: We'll go next to Mohit Bansal with Wells Fargo.
Speaker Change: Great. Thank you very much for taking my question and Albert one more for you.
Speaker Change: Pharmaceutical manufacturing a little bit more complex the alere.
Speaker Change: Manufacturing.
Substance as well as the fill finish and to my understanding. The fill finished majority of part is already in the U S. But would love to understand from your conversations is there a specific focus of that decision to bring the API part of it.
Speaker Change: Substance manufacturing part of it to the U S and how feasible it is to be API.
Speaker Change: We do some friendly countries if not if not America.
Speaker Change: I would love to get your perspective on that thank you.
Speaker Change: Yes.
Speaker Change: Thank God for things that they are considered their national security. They are looking at the entire value chain.
Speaker Change: So they want to see the precursors the AP is and whether the products are made.
Speaker Change: And they are making very clear of the 6% I think on what those products are made so that they can assess various transferred manufacturing even under the.
Speaker Change: Most lucrative investments so valuable and even under the most favorable.
Speaker Change: Regulatory framework to provide approvals et cetera, it's a multi multiyear process always about something about this can be resolved within a year. So I believe they will focus on a manageable number of products that are of most importance of it can be.
Bill and secured versus unsecured, but I think the questions retina, we saw leverage on API simple crushers, where.
Speaker Change: But where the products are made visit.
Speaker Change: Next question please.
Speaker Change: We'll go next to Courtney brain with Bernstein.
Speaker Change: Okay.
Speaker Change: Hi, everyone. Thanks for taking the time.
Speaker Change: Question today.
Speaker Change: A couple that we had won one clarification on tariffs.
Speaker Change: Apologies, if we missed it but this is just kind of if you can provide any comments on inventory and kind of what youre doing already to bring inventory into the U S. And then the second question is just on the pipeline I know kind of you can add some details about the things that you were looking to prioritize.
Speaker Change: But can we expect an R&D day.
Speaker Change: At some point this year that will help us better understand the overall pipeline strategy and help us understand that reallocation and perhaps even better assess and evaluate that pipeline and our sell side models.
Speaker Change: Thank you Rick Correct me I will ask Chris to comment on the pipeline, but on the tires that David also said I think in the beginning.
Speaker Change: You can imagine we have done everything that we have to do to make sure that we meet the gate. So I conclude soon but those of course and many other things, but we have built into the confidence so that we can weather.
Speaker Change: Any scenario.
Speaker Change: You submit it.
Speaker Change: Every month, we increasingly proficient so to make sure about the as I said I think rainy days, we are well positioned Chris on pipeline.
Speaker Change: So thank you for the question just a reminder, we've got a number of products that we currently excited about that would readout. Later this year for instance, Todd said massive invasive that's positive it will triple.
Speaker Change: Couple the population outbreaks.
Speaker Change: <unk> mentioned double classic exposed will double the population Sunday map RPC readout, just now potentially up to 38000 patients eligible in the U S.
Speaker Change: And then a number of phase III programs, we are celebrating or that already started or will start later this year.
Speaker Change: Over the next six to nine months, including oncology two Adcs Albert mentioned CCAR to attack the dosing PDL won't be <unk>, continuing face to face one I'm, sorry phase III in first line <unk> positive breast cancer and vaccines PCB post generation, but also potentially starting first and only two market opportunity with a C.
Speaker Change: <unk> vaccine and internal medicine, sacral map, which again and discovered in house potential brand new opportunity. This is opening a new field.
Speaker Change: In cancer Cachexia in terms of an R&D day, we're not planning it but as you know we currently have the flashes which is organized by.
Speaker Change: By our IR team. The next one coming up will be on breast cancer, and we will continue throughout the year the splash and.
Speaker Change: And in general all.
Speaker Change: Our intention is to provide as much visibility.
Speaker Change: Our data are possible.
Speaker Change: Possible without undermining publications of course, so I think the flashes are making very good.
Speaker Change: It's all right now and we can intensify also how we do that so that we have smaller bites.
Speaker Change: My son.
Speaker Change: I was referring to a specific product that enough of a month that neither product went up a fair amount of our product rather than.
Speaker Change: Yeah.
Speaker Change: It's sour everyone with a lot of data and the information in one day, but.
Speaker Change: We will find the best way and to our listening right now we are listening.
Speaker Change: All Oh I noticed that they are giving us a vehicle that we are listing all our investors, but they are giving us ideas on how best to communicate our pipeline.
Speaker Change: Let's go now to the next question.
Speaker Change: Yes.
Speaker Change: We'll go next to <unk> <unk> with Goldman Sachs.
Speaker Change: Thanks, Thanks for taking the questions and thanks for all the color on the macro and clarified.
Speaker Change: I'll ask a couple of product specific questions.
Speaker Change: Just on <unk> can you just double click on how competitive dynamics are playing out in that market relative to your own expectations.
Speaker Change: Second on the internal oral <unk> agonist can you remind us of the timelines on when we start to see more data and then third on these nine phase III readouts that you're highlighting other than <unk>, which you've highlighted in the past where do you see the biggest disconnect in analyst models relative to your own internal expectations. Thank you.
Speaker Change: Amir you talk about <unk>.
Speaker Change: Chris maybe you explained on <unk> and Andrew you can speak about where are the biggest differences are.
Speaker Change: Okay.
Speaker Change: Thanks for the question on vendor in the U S. I think we are off to a very good start in the new year with growing revenue at 31% and that is a combination of multiple things, including the fact that diagnosis rates are improving we've improved access and therefore have had.
Speaker Change: Strong new patient starts certainly versus last year more than 70% and versus Q4, almost 20% new patient start growth.
Speaker Change: And continued compliance with our existing base of patients and all of that has driven very very strong volume growth year over year and sequentially.
Speaker Change: And we are managing that revenue growth. Despite the offset of the impact of IRI part D redesign that Dave spoke to now we're obviously seeing impact of competition principally.
Speaker Change: <unk> and principally on newly diagnosed patients will continue to stay close and monitor that and how that evolves and how our leuctra settles into the market as well, but the year is off to a good start our team is executing well and we have confidence we will grow for the balance of it.
Speaker Change: Alexander can you comment also on pinnacle in the international markets is growing very healthy overall, yeah facility. So we had also.
Speaker Change: A good growth of 36% this quarter above expectation from the Aneth is what's driving that is essentially a significant increase in our treated population. We are actually reach a 52% of gross in patients treated from tinder in Q.
Speaker Change: Q1 versus Q1 last year, so very healthy trends and we see that this trend will continue play essentially three reason one because all Jack knows he's right that has potential to expand in pretty much all our key markets outside of the U S too because the profile of clinical profile is differentiated and will support alternative cash taxes would be.
In the U K market and tree, which is often underestimate that we after three years of hard work finally, rich access reimbursement in 46 States and we just we see it actually reimbursement in Korea in Marshall County, 25, so that will kind of.
Speaker Change: Blue into our business and we'll continue to sustain this significant growth.
Chris Guiffre: Thank you Alexander Chris Guiffre, and oral small molecule <unk> antagonist was discovered in house, it's potentially first in class oral small molecule get that tightness and the peace Phase II study now ongoing. This he says studying obesity in combination with a good tight with the G. L. P. One the PCB is listed on clinical trials data.
Chris Guiffre: Got to the end of 2025 suspect beginning 2026 potential data if the data are positive in the phase II study then it could be a potential to be used in combination to drive weight loss, both with internal or external opportunities.
Speaker Change: It was very much Chris and then Andre.
Chris Guiffre: Disconnect between our projections that you came to interrogate very carefully.
Speaker Change: Europe Paul.
Alex: Alex in your previous life, Alright, well, thank you for the opportunity.
Speaker Change: So I'd start with the two adcs, which are now in phase III first line trials.
Alex: Small cell and <unk>.
Alex: <unk> head and neck, so SP and PDL Onesie now part of the reason I think that the street may have.
Alex: May have flown under the radar is they moved very very quickly on the back of very strong phase one data straight into phase III. So I think some some focus on that will be useful. We obviously have the benefits of having seen access to more data than you have but we look forward to sharing that with you in the near future and hopefully that would align your expectations.
Alex: Closer to as intently.
Alex: Chris already mentioned C diff.
Speaker Change: Which will begin a phase III end of this year beginning of next year, a very significant unmet medical need and then and this is not by any means a comprehensive list, but the two other ones I would mentioned is the CDK four which I named Chuck previously, which builds on a legacy <unk>.
Speaker Change: And class a promise as much better tolerability and efficacy again, it's in a frontline head to head trial versus the current standard of cats.
Speaker Change: And that is a $15 billion plus markets have very sizable in areas that we have a lot of expertise in and then the final one is <unk>, which have addressed before look we need to see how the data pans out.
Speaker Change: It translates into a meaningful.
Speaker Change: At progression free survival benefit or even a survival benefit then obviously, it's a it's a home run in terms of the value set those patients but in addition, the revenue potential alternative to the sport to cast therapy, and that's still a significant product, albeit at a different price points in a different order of magnitude, but nonetheless, there was a very substantial delta.
Speaker Change: When we look further out between what I can see a we can see and how the street is modeling some of the school costs. So we look forward to hopefully narrowing the gap.
Speaker Change: In the months ahead. Thank you Andre move upwards as the last question then.
Speaker Change: Couple of comments, we've had a very solid performance in the first quarter keep in mind that the already $650 million negative in the U S have been already absorbed in the results of the first quarter because of higher rates and the votes from <unk> 1 billion net wanted the half gross for the year, but so we'd say it.
Speaker Change: He has a very strong start I think in the strategic priorities. We continue to guide us in marketing on our greatest opportunity. The discipline will continue I think the team that too.
Speaker Change: Have a running right now the company.
Speaker Change: Probably the best I have ever seen in Pfizer and Pfizer have traditionally very very strong finish and so on.
Speaker Change: Cautiously optimistic that we will turn this around.
Speaker Change: We will.
Speaker Change: Slate they are very good operational performance over the last.
Speaker Change: Five quarters at least.
Speaker Change: Also meaningful shareholder value. Thank you very remarks, and the people are.
Speaker Change: And the next earnings call.
Speaker Change: This does conclude today's program. Thank you for your participation you may disconnect at any time.
Speaker Change: Hum.
Speaker Change: [music].
Speaker Change: Sure.
Speaker Change: [music].
Speaker Change: Okay.
[music].
Speaker Change: Hello, Matt.
Speaker Change: [music].
Speaker Change: Okay.
Speaker Change: Yeah.
Speaker Change: Yeah.
Speaker Change: Okay.
Speaker Change: Yeah.